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Abstract: 
 
Background and Aims: Silymarin, an extract from the seeds of the milk thistle plant Silybum 
marianum, has been used for centuries for the treatment of chronic liver diseases. Despite 
common use by patients with hepatitis C in the U.S., its clinical efficacy remains uncertain. The 
goal of this study was to determine if silymarin has in vitro effects on immune function that 
might have implications for its potential effect on HCV-induced liver disease. 
 
Methods: Freshly isolated PBMC and T cells from HCV-infected and uninfected subjects were 
tested in vitro for responses to nonspecific and antigenic stimulation in the presence and absence 
of a standardized preparation of silymarin (MK001). 
 
Results: Minimal MK001 toxicity on PBMC was found at concentrations between 5-40 μg/mL. 
MK001 dose-dependently inhibited the proliferation and secretion of TNF-α, IFN-γ, and IL-2 by 
PBMC stimulated with anti-CD3. In addition, MK001 inhibited proliferation by CD4+ T cells to 
HCV, Candida and Tetanus protein antigens, and by HLA-A2/HCV1406-1415-specific CD8+ T 
cells to allogeneic stimulation. MK001 inhibited T cell TNF-α and IFN-γ cytokine secretion to 
Tetanus and Candida protein antigens. Finally, MK001 inhibited NF-κB transcriptional 
activation after T cell receptor-mediated stimulation of Jurkat T cells, consistent with its ability 
to inhibit Jurkat T cell proliferation and secretion of IL-2. 
 
Conclusion: Silymarin’s ability to inhibit the proliferation and pro-inflammatory cytokine 
secretion of T cells, combined with its previously described anti-viral effect suggests a possible 
mechanism of action that could lead to clinical benefit during HCV infection. 
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Article:  
 
Chronic hepatitis C afflicts approximately 3 million individuals and is the leading cause of end-
stage liver disease requiring transplantation in the United States. Liver fibrosis progression, the 
major consequence of chronic infection, generally occurs over decades in immunocompetent 
individuals.1 
 
The current standard treatment for HCV infection, pegylated interferon and ribavirin, results in 
an overall sustained virologic response (SVR) rate of approximately 55%, which, in the vast 
majority of cases represents durable viral eradication.2, 3 However, significant numbers of 
patients do not achieve an SVR, or are intolerant/have contraindications to therapy. 
Complications of hepatitis C-induced liver fibrosis including liver failure and cancer are 
predicted to increase significantly over the next twenty years, and no other treatment options are 
currently available.4 Thus, many individuals have turned to herbal remedies. Two recent studies 
have reported that as many as 13% to 23% of U.S. patients with chronic liver disease are using 
herbal remedies, with silymarin being the most common preparation ingested for such purpose.5,6 
 
Silymarin, an extract from the seeds of the milk thistle plant, Silybum marianum, has been used 
for centuries as a “hepatoprotectant”. Silymarin is a mixture of seven flavonolignans (silybin A, 
silybin B, isosilybin A, isosilybin B, silychristin, silydianin, and isosilychristin) and one 
flavonoid (taxifolin). Although its mechanism of action is incompletely understood, silymarin 
has been described to possess anti-oxidant, immunomodulatory, anti-fibrotic, anti-proliferative 
and anti-viral activities.7, 8 Silymarin’s clinical efficacy in chronic liver disease has not yet been 
demonstrated,9, 10 as results have been inconsistent. Problems with the studies have included 
insufficient power, use of varying doses (including those that may be too low to have an effect), 
and the use of different nonstandardized preparations of silymarin, making it difficult to compare 
results among studies. Moreover, many reports have utilized silibinin or chemically modified 
silibinin, a ~50:50 mixture of silybin A and silybin B, rather than silymarin. 
 
HCV is generally believed to be a noncytopathic virus and hepatic fibrosis in hepatitis C is 
thought to be the end result of long-standing inflammation, characterized by the accumulation of 
CD4+ and CD8+ T cells in the infected liver. A substantial amount of data suggests that HCV-
specific T cell cytokine and cytolytic responses as well as “bystander” effects contribute to 
immune-mediated liver injury.11 As an important component of the inflammatory response to 
HCV infection, T cells are stimulated to proliferate, secrete cytokines, and kill infected cells. In 
this study, we investigated whether a standardized preparation of silymarin (MK001) can affect 
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pro-inflammatory immune responses, such as T cell proliferation and cytokine secretion, as a 
means of providing hepatoprotection. 
 
MATERIALS AND METHODS 
 
Subjects 
 
Healthy subjects and those with chronic HCV infection were recruited at Harborview Medical 
Center after written informed consent was obtained through a University of Washington (UW) 
Institutional Review Board-approved protocol. 
 
Silymarin 
 
A standardized preparation of silymarin (MK001)8 was used in all experiments. Using HPLC 
analyses with detection at 254 nm, all peaks more than 0.7% in quantity have been assigned, and 
the total flavonolignan content was 92%. MK001 was solubilized in DMSO, 95% ethanol or 
methanol. Control samples were treated with the same concentration of DMSO, 95% ethanol or 
methanol as used in the MK001-treated samples. Silybin A, silybin B, and silibinin were purified 
as previously described in detail.12 
 
PBMC Isolation and Stimulation 
 
All peripheral blood mononuclear cells (PBMC) were freshly isolated using standard Ficoll-
Hypaque centrifugation within 24 hours of venipuncture and immediately applied to the assays 
described. 
 
PBMC were stimulated for varying periods of time at 37°C 5%CO2 with plate-bound anti-CD3 
(UCHT1, 10 μg/mL, BD Biosciences, San Jose, CA), anti-CD3 and anti-CD28 Dynabeads 
(Invitrogen, Carlsbad, CA), phytohemagglutinin (PHA, 1.6 μg/mL, Remel, Lenexa, KS) or 
PMA/ionomycin (50 ng/mL of PMA and 1μg/mL ionomycin, both, Sigma Aldrich, St. Louis, 
MO) in RPMI 1640 medium supplemented with 10% human serum (Gemini Bio-Products, 
Woodland, CA). Stimulation with Tetanus and Candida protein antigens was performed as 
described under proliferation assays (below). 
 
Cellular Proliferation Assays 
 
Cellular proliferation detected by 3H-thymidine incorporation into replicating DNA was 
measured by adding 1 μCi to each replicate well of 105 PBMC for 24 hours (for α-CD3 and PHA 
experiments) or 16-18 h (for protein antigen experiments) before quantitative analysis using a 
Topcount® Liquid Scintillation Counter (Perkin-Elmer, Waltham, MA). In general, data are 
presented as mean counts per minute (cpm) incorporated per condition tested. All experiments 
utilized four replicates per condition. 
 
To measure HCV-specific proliferative responses, PBMC were incubated with superoxide 
dismutase (SOD)-recombinant HCV protein antigens (courtesy of Dr. Michael Houghton and 
Kevin Crawford, Chiron Corp.) at a final concentration of 10 μg/mL for 5 days prior to addition 
of 3H-thymidine as described above.13 Antigens included yeast-derived SOD (negative control), 
SOD-c22 (HCV aa 2-120), SOD-c100 (HCV aa 1569-1931), SOD-NS5 (HCV aa 2054-2995), 
and E. coli-derived SOD-c33c (HCV 1192-1457). PHA (1.6 μg/ml, Remel), Candida albicans 
(20 μg/mL, Greer Laboratories, Lenoir, NC), and Tetanus toxoid (12 Lf/mL, Wyeth-Ayerst 
Laboratories, Marietta, PA) were also tested. Assays were considered valid only when PHA 
responses were intact. 
 
PBMC and T cell proliferation was also measured using carboxyfluoroscein succinimidyl ester 
(CFSE) dilution. PBMC were exposed to 1 μM CFSE (Invitrogen/Molecular Probes, Carlsbad, 
CA) for 10 min at 37°C, then washed and cultured with or without stimulation and with or 
without MK001 (20 μg/mL) at 37°C, 5% CO2. The next day, cells were labeled with the 
following fluorescent surface antibodies (all BD Biosciences): α-CD5-PerCP-Cy5.5, α-CD8-PE, 
α-CD45-APC and fixed with 1% paraformaldehyde and analysed by flow cytometry as described 
below. For T cell experiments, HCV 1406-1415-expanded T cells were cultured with allogeneic 
B-LCL at a ratio of 10:1 (T cells: BLCL), with or without MK001 (20 μg/mL) for 3 days before 
labeling with α-CD8-PerCP, α-CD3-APC (both BD Biosciences) and HLA-A2 HCV 1406-1415 
pentamer-PE (ProImmune, Bradenton, FL). 
 
Flow Cytometric Analysis of Cell Viability 
 
Cellular viability was measured after labeling with Live/Dead Fixable Dead Cell Stain Kit 
(Violet viability dye, Invitrogen/Molecular Probes, Carlsbad, CA) for 24 hours and analyzed 
using a Becton Dickinson FACS Calibur (Puget Sound Blood Center, Seattle, WA) and FlowJo 
software for Macintosh (version 6.3.3, Treestar, Inc., Ashland, OR). 
 
Intracellular Cytokine Staining 
 
PBMC were stimulated with negative controls (DMSO, 95% ethanol, or media) or plate-bound 
anti-CD3 (10 μg/mL), or PHA (1.6 μg/mL) in the presence and absence of MK001, and treated 
with 1 μg/mL Brefeldin A (Sigma-Aldrich, St Louis, MO). After a total of 16 hours, cells and 
labeled with the following surface markers: Live/Dead Fixable Dead Cell Stain Kit, α-CD5-
PerCP-Cy5.5 (BD Biosciences), α-CD8-ECD (Beckman Coulter), α-CD4-APC-Cy7, and α-
CD56-biotin (BD Biosciences) plus QDot605-streptavidin (Invitrogen, Molecular Probes). Cells 
were treated with BD Cytofix/Cytoperm (BD Biosciences), washed with BD Perm/Wash, and 
intracellular staining performed using TNF-α-APC (BD Biosciences) and IFN-γ-PE-Cy7 (BD 
Pharmingen). All samples were fixed at a final concentration of 1% paraformaldehyde and 
analyzed on a BD LSR II (BD Biosciences, Fred Hutchinson Flow Cytometry Center) with 
compensation and data analysis performed using FlowJo software. 
 
Cytokine Detection by ELISA 
 
Supernatants were collected 24 hours after stimulation at 37°C, 5% CO2, and immediately frozen 
at −80°C. These samples were subsequently tested for the presence of TNF-α, IFN-γ, IL-2, and 
IL-10 at the Fred Hutchinson Cancer Research Center Cytokine Analysis Facility, Seattle, WA, 
using standard ELISA kits or using multiplex immunobead ELISA (Biosource/Invitrogen) and 
the Luminex® xMAP system. 
 
Jurkat T cell transfection and measurement of NF-κB-dependent transcription 
 
Transient transfections of Jurkat T cells were performed using Cell Line Nucleofector Kit V 
according to manufacturer’s instructions (Amaxa, Gaithersburg, MD). Briefly, in 12 well plates, 
5 × 106 cells/well were electroporated using program S-18 and 5 μg of a plasmid encoding a 
luciferase reporter gene under the control of an NF-κB responsive promoter. Forty-eight hours 
later, cells were treated or not treated with 20 μg/mL of MK001 in DMSO for 30 minutes. NF-
κB transcription was activated via the TCR using plate-bound anti-CD3 (10 μg/mL), anti-CD3 
(10 μg/mL) + soluble anti-CD28 (1 μg/mL) antibodies, or with rhTNF-α (15 ng/mL, Pierce 
Biotechnology, Rockford, IL). Four hours later, luciferase acitivity was measured on cell lysates 
using the Britelite assay system (Perkin-Elmer, Boston, MA). 
 
 
 
Figure 1. Minimal effects of silymarin on cell viability 
PBMC from representative HCV-infected subjects were cultured with media, and with various concentrations of 
MK001 dissolved in DMSO or ethanol vehicle or with corresponding vehicle controls (DMSO or ethanol alone) for 
24 hours. PBMC were unstimulated (A) or stimulated with anti-CD3 (B) at culture initiation. Cells were labeled 
with Live/Dead Fixable Dead Cell Stain Kit (Violet viability dye, x-axis) and analyzed by flow cytometry. Non-
viable cells take up the dye, and the percentage of non-viable cells is indicated in the upper right corner of each plot. 
Positive control samples treated with PMA/ionomycin for 24 hours exhibited significant cell death (bottom left, 
panels A and B). Similar results were found upon analysis of the CD4+ and CD8+ T cell compartments for both 
unstimulated and stimulated cells. Two additional experiments from uninfected subjects demonstrated similar results 
(data not shown). 
 
RESULTS 
 
Cellular Toxicity of MK001 
 
 
 
 
 
Figure 2. MK001 inhibition of PBMC proliferation is dose dependent 
For all assays, a single dose of MK001 was added at culture initiation and compared to parallel cultures treated with 
a single dose of MK001 vehicle (DMSO or EtOH). Freshly isolated PBMC were tested in quadruplicate for 
proliferative responses to plate-bound anti-CD3 (10 μg/mL) (A, B) or PHA (1.6 μg/mL) (C, D) stimulation 
measured at 24 hours using 3H-thymidine incorporation. Results are shown as mean cpm incorporated in cultures 
treated with MK001 at various doses (black bars) or with the corresponding vehicle control (Ethanol or DMSO, 
open bars). Gray bars represent proliferation of PBMC stimulated with anti-CD3 or PHA alone. Error bars indicate 1 
standard deviation among 4 replicates for each condition. PBMC for representative dose response experiments 
shown were obtained from HCV-infected (A) and HCV-uninfected (C) subjects. Similar dose response results were 
obtained in 5 additional HCV-infected and 1 additional HCV-uninfected subjects. Results from individual HCV-
infected and uninfected subjects tested with MK001 (20 μg/mL) are also shown (B, D). Results from MK001-treated 
samples were statistically different from vehicle-treated samples (Wilcoxon matched pairs test, p=0.03 for anti-CD3 
or PHA separately). 
 
PBMC from HCV-infected subjects were cultured for 24 hours with various concentrations of 
MK001, a standardized preparation of silymarin, to assess whether any toxic effects could be 
detected (Figure 1). Controls included co-culture with media alone and various DMSO, and 
ethanol concentrations, corresponding to various doses of MK001 tested. Viability of 
unstimulated (Figure 1A) and anti-CD3-stimulated (Figure 1B) PBMC as well as CD8+ and 
CD4+ T cell subsets was assessed using the Live/Dead Fixable Dead Cell Stain Kit and flow 
cytometric analysis as described in Materials and Methods. The percentage of non-viable cells 
taking up the dye is indicated in the upper right corner of each plot. These data demonstrate that 
the minor toxicity of co-culture with MK001 was due primarily to the effects of the vehicle, not 
MK001. Significant cellular toxicity consistently occurred at a dose of 100 μg/mL for 24 hours, a 
dose 5-fold higher than that used for most of the experiments included in this report (20 μg/mL). 
PBMC viability was also assessed using trypan blue exclusion after the addition of a single dose 
of various MK001 concentrations; viability was 99% and 97% after 24 hours and 5 days, 
respectively, at 20 μg/mL. In all subsequent experiments (excluding dose response experiments), 
MK001 was used at a concentration of 20 μg/mL or ~40 μM. 
 
MK001 dose-dependently inhibits PBMC and T cell proliferation 
 
During an immune response to viral infection, an important component of the response is the 
proliferation of antigen-specific T cells. We asked whether MK001 had the ability to inhibit 
antigen-specific and non-specific proliferation of freshly isolated PBMC and T cells from HCV-
infected and uninfected subjects. A single dose of MK001 at culture initiation was able to dose-
dependently inhibit proliferation of freshly isolated PBMC stimulated nonspecifically with anti-
CD3 (Figure 2A) or PHA (Figure 2C). As shown in Figure 2B, inhibition of proliferation by 
MK001 (20 μg/mL) ranged from 54-78% (mean 70%) in 5 unique individuals (2 HCV-
uninfected and 3 HCV-infected) using a standard 3H-thymidine incorporation assay and plate-
bound anti-CD3 as the stimulant. A similar degree of inhibition was detected using PHA (23-
79%, mean 48%) to stimulate cells from the same subjects (Figure 2D). In addition, purified 
preparations of milk thistle extract, silibinin, silybin A and silybin B induced similar inhibitory 
effects on PBMC proliferation (Supplemental Figure 1A). 
 
CFSE dilution by flow cytometry is another method of measuring cellular proliferation; CFSE is 
bound by cytoplasmic proteins and progressively diluted as daughter cells divide. Proliferation of 
both CD8+ and CD8− (equivalent to CD4+) T cells was demonstrated using this method with 
anti-CD3 stimulation (Figure 3A). The addition of MK001 led to inhibition of proliferation 
measured 24 hours later. Finally, the addition of MK001 (20 μg/mL) to PBMC stimulated by 
HCV protein antigens as well as Tetanus and Candida antigens (Figure 3B) resulted in inhibition 
of proliferative responses measured using 3H-thymidine incorporation. In this latter assay, 
proliferative responses are found exclusively in the CD4+ T cell subset (data not shown). 
 
To demonstrate that MK001 can also inhibit the proliferation of HCV antigen-specific cells, 
HCV1406-1415-expanded PBMC from an HLA-A2+ HCV-infected subject were evaluated. 
HCV-antigen-specific T cells proliferated in response to allogeneic stimulation (Figure 3C, left 
panel), as evidenced by the loss of CFSE fluorescence. Addition of MK001 at culture initiation 
resulted in an inhibition of CFSE dilution in both HCV-1406-1415-specific and non-specific T 
cells (Figure 3C, histograms). 
 
MK001 inhibits pro-inflammatory cytokine secretion by stimulated human T cells in vitro 
 
Pro-inflammatory cytokine secretion can lead to the amplification of the immune response. Thus, 
we asked whether MK001 could affect the secretion of TNF-α, IFN-γ and IL-2 from PBMC, 
freshly isolated from HCV-infected and uninfected donors. As shown in Figure 4 (A, C and E), 
TNF-α, IFN-γ and IL-2 secretion by anti-CD3 stimulated PBMC was dose-dependently inhibited 
by MK001. Furthermore, testing of PBMC from an additional 3 HCV-infected and 2 uninfected 
individuals using MK001 (20 μg/mL) demonstrated consistent results (Figure 4: B, D, and F). 
Inhibition of cytokine secretion ranged from 47-86% (mean 70%) for TNF-α, 58-83% (mean 
68%) for IFN-γ and 53-87% (mean 71%) for IL-2. Treatment with MK001 alone had no effect 
on unstimulated PBMC (data not shown). PBMC treated with components purified from milk 
thistle extract, silibinin, silybin A and silybin B also inhibited anti-CD3-stimulated IFN-γ 
responses in a dose-dependent manner (Supplemental Figure 1B). 
 
 
 
 
Figure 3. MK001 Inhibits antigen-specific and nonspecific T cell proliferation 
For all assays, a single dose of MK001 (20 μg/mL) was added at culture initiation and compared to parallel cultures 
treated with a single dose of vehicle alone (DMSO). (A) Fresh PBMC from a representative HCV-infected subject 
was exposed to CFSE for 10 minutes, then washed and cultured with media, anti-CD3 (platebound,10 μg/mL) alone, 
anti-CD3 + DMSO, or anti-CD3 + MK001 in DMSO overnight. Flow cytometric analyses of live CD45-expressing 
lymphocytes that were also CD5-positive allowed the detection of cell proliferation in both CD8− (left panel) and 
CD8+ (right panel) T cell populations. Y-axis indicates the percentage of maximum cell number (note offset 
histograms). CD8−CD5+ T cells were confirmed to be CD4+CD5+ T cells, equivalent to CD8−CD3+ and 
CD4+CD3+, respectively (data not shown). (B) Freshly isolated PBMC from two HCV-infected subjects were 
exposed to HCV and recall antigens, and PHA for 5 days, as described.13 Results are shown for 3H-thymidine uptake 
measured in mean cpm (counts per minute) incorporated into replicate cultures treated (black bars) or untreated 
(open bars) with MK001. HCV-specific responses considered to be significantly inhibited (HCV-positive to HCV-
negative) are indicated by the asterisks. Similar results were obtained from 4 additional HCV-infected subjects. The 
threshhold for a positive HCV-specific response was a stimulation index of >4.0. Error bars indicate 1 standard 
deviation among 4 replicates for each condition. (C) T cells from an HCV-infected HLA-A2+ subject were 
expanded from PBMC using the 9-mer HCV 1406-1415 and rhIL-2 at 37°C, 5% CO2 for 12 days. Cells were 
exposed to CFSE for 10 minutes, then washed and cultured with allogeneic B-LCL with MK001 (20 μg/mL) in 
DMSO or with DMSO alone. Three days later the cells were surface labeled with fluorescently conjugated anti-
CD3, anti-CD8 and pentamer HLA-A2-HCV NS3 1406-1415 and analyzed using a BD FACS Calibur and FlowJo 
software. Live lymphocytes that express CD3 and CD8 were gated upon. Shown in the upper right quadrant are cells 
that bind the pentamer and contain CFSE. Cells that have divided are CFSE-negative and are found in the left 
quadrants. Offset histogram plots indicate the difference in cellular proliferation between MK001 (gray) and DMSO 
(vehicle, white)-treated pentamer-positive (top) or pentamer-negative (bottom) T cells. 
 
 
 
 
 
 
 
Figure 4. MK001 dose-dependently inhibits TNF-α, IFN-γ, and IL-2 secretion by stimulated 
human PBMC in vitro 
PBMC from an HCV-infected subject were stimulated with plate-bound anti-CD3 (10 μg/mL) or negative controls 
(95% EtOH or media) in the presence of MK001 (in 95% EtOH) or vehicle alone. Supernatants collected 24 hours 
after stimulation were tested by multiplex ELISA for the presence of TNF-α (A), IFN-γ (C),or IL-2 (E) as described. 
White bars indicate samples treated without MK001 but with vehicle, black bars indicated samples treated with 
MK001 in vehicle. Gray bars represent proliferation of PBMC stimulated with anti-CD3 alone. PBMC from 
additional HCV-infected and uninfected control subjects were tested similarly and the consistent effect of MK001 
(20 μg/mL) on TNF-α (B), IFN-γ (D), and IL-2 (F) secretion is shown. Similar dose response results to those shown 
were found using PBMC from both an HCV-infected and an uninfected subject. Results from MK001-treated 
samples were statistically different from vehicle-treated samples (Wilcoxon matched pairs test, p=0.03 for each 
cytokine separately). 
  
 
Figure 5. T cell secretion of TNF-α, IFN-γ, and IL-2 is inhibited by MK001 
(A) PBMC from an HCV-infected subject were enriched for T cells and cultured with 0.5% DMSO or media (not 
shown) or plate-bound anti-CD3 (10 μg/mL) in the presence of MK001 (20 μg/mL) or vehicle (DMSO) for 24 
hours. TNF-α, IFN-γ, and IL-2 levels in culture supernatants were evaluated using multiplex ELISA. Detection 
limits were 2 pg/mL, 2 pg/mL, and 4 pg/mL, respectively. (B) Purity of enriched CD3+ T cells used in (A) was 
assessed using flow cytometric analysis, gating on CD45+ live lymphocytes (NB: purity was 97.5% without gating). 
(C) PBMC from a second HCV-infected subject were stimulated with negative controls (DMSO or media) or plate-
bound anti-CD3 (10 μg/mL), or PHA (1.6 μg/mL) in the presence of MK001 (20 μg/mL) or vehicle (DMSO) for 16 
hours. Intracellular TNF-α and IFN-γ cytokine expression were evaluated in the presence of 1 μg/mL brefeldin A. 
Violet viability dye was used to distinguish live cells (from dead), and cells were further selected on the basis of 
CD5 expression and the absence of CD56 expression. TNF-α expression (x-axis, left panels) and IFN-γ (x-axis, right 
panels) from live CD5+CD8+CD56- lymphocytes are shown in the upper right quadrant. Percentages of cells in 
each quadrant are displayed. Cytokines detected in the CD5+CD8-CD56- population were confirmed to derive from 
CD5+CD4+CD56- cells in the same experiment, and CD5+CD8+ T cells previously confirmed to represent the 
same population as CD3+CD8+ T cells (data not shown). 
 
To specifically investigate whether T cell secretion of these cytokines was inhibited, we utilized 
a highly enriched population of T cells (99.4% purity, Figure 5B) and compared the levels of 
TNF-α, IFN-γ and IL-2 in culture supernatants after 24 hours (Figure 5A). These data 
demonstrated a strong inhibition of pro-inflammatory cytokine secretion specifically by T cells 
as a result of MK001 treatment. Furthermore, intracellular detection of cytokines TNF-α and 
IFN-γ was reduced in CD8+ and CD8− (CD4+) T cells after culturing in the presence of MK001 
compared to the DMSO vehicle control using flow cytometric analysis (Figure 5C). 
 
The effect of MK001 on cytokine secretion by antigen specific T cells was examined using fresh 
PBMC from two unique HCV-infected subjects (Figure 6). Tetanus and Candida-specific TNF-α 
and IFN-γ responses, quantified by ELISA, were similarly inhibited by treatment with MK001 
(20 μg/mL). 
 
  
  
Figure 6. Inhibition of TNF-α and IFN-γ secretion by Tetanus toxoid and Candida albicans-
specific T cells 
Fresh PBMC from two representative HCV-infected subjects (A, C and B, D) were cultured with Tetanus and 
Candida protein antigens and PHA, with or without MK001 (20 μg/mL) for 4 days. Culture supernatants were 
frozen at −80°C and subsequently tested by multiplex ELISA for the presence of TNF-α and IFN-γ (sensitivity of 
detection: 2 pg/mL for both). No cytokine secretion was detected in the absence of protein antigens. Similar results 
were obtained in 5 HCV-infected and 2 HCV-uninfected subjects. 
 
MK001 inhibits proliferation, IL-2 secretion and NF-κB-mediated transcription in the Jurkat T 
cell line 
 
Since silymarin has been shown to inhibit NF-κB activation,7 we asked whether NF-κB blockade 
could account for the inhibition of cellular proliferation and cytokine secretion. To investigate 
this possibility, we utilized the transformed Jurkat T cell line, which proliferates spontaneously. 
A single dose of MK001 was able to inhibit Jurkat T cell proliferation measured by 3H-
thymidine incorporation 24 hours later (Figure 7A). Stimulation with anti-CD3 alone was 
insufficient to induce cytokine secretion in Jurkat cells (data not shown), but stimulation with 
anti-CD3 and anti-CD28 antibodies together resulted in IL-2 secretion. (NB: Stimulation of 
Jurkat T cells with anti-CD3 and anti-CD28 together does not induce TNF-α or IFN-γ secretion, 
data not shown). Therefore, we tested whether MK001 could inhibit IL-2 secretion from Jurkat T 
cells. Our data indicate that MK001 was indeed able to inhibit IL-2 secretion from Jurkat T cells 
as measured by standard ELISA (Figure 7B). Finally, to determine whether inhibition of NF-κB 
might also be occurring, Jurkat T cells were transfected with a plasmid containing a luciferase 
reporter gene under the control of an NF-κB responsive promoter. These data, shown in Figure 
7C, indicate that treatment with MK001 resulted in a dose-dependent inhibition of T cell 
receptor-induced NF-κB activation. We also investigated whether MK001 could affect IL-10 
secretion, indirectly limiting pro-inflammatory responses, but found that IL-10 secretion by 
PBMC was also inhibited in the presence of MK001 (Supplemental Figure 2). 
 
 
 
 
Figure 7. MK001 inhibits proliferation, IL-2 secretion, and NF-κB-mediated transcription in the 
Jurkat T cell line 
(A) Spontaneous proliferation of the human Jurkat tumor cell line was detected using 3H-thymidine incorporation 
(mean cpm of quaduplicate wells). Results from parallel cultures treated with MK001 (20 μg/mL) dissolved in either 
DMSO or 95% ethanol are shown in this representative experiment. (B) Jurkat T cells were stimulated to produce 
IL-2 using plate-bound anti-CD3 and soluble anti-CD28 stimulation, and compared to the negative control (95% 
ethanol) and MK001 (20 μg/mL) treatment. IL-2 was quantified in supernatants collected 24 hours after stimulation 
using ELISA. (C) Jurkat T cells were transfected with 5 μg of a plasmid encoding a luciferase reporter gene under 
the control of an NF-κB responsive promoter. Cells were treated with MK001 or DMSO for 30 minutes prior to 
stimulation. (No cellular toxicity has been noted with the MK001 concentrations used at 30 minutes, data not 
shown). NF-κB transcription was activated via the TCR using plate-bound anti-CD3, anti-CD3 + anti-CD28 
antibodies, or with 15 ng/mL TNF-α, and luciferase activity was measured 4 hours after TCR activation or TNF-α 
treatment. Treatment with MK001 resulted in a dose-dependent inhibition of TCR-induced NF-κB activation. Error 
bars in all panels indicate one standard deviation among 4 replicates per condition. 
 
DISCUSSION 
 
Hepatic inflammation in chronic liver disease is histologically evaluated by the extent of 
infiltration by lymphocytes and the degree of hepatocyte cell death or necrosis, usually near 
lymphocyte aggregates.21 Clinical studies have demonstrated a clear association between greater 
hepatic inflammation and subsequent fibrosis progression.14, 15 Thus, control of inflammation is 
likely to be a useful strategy for ameliorating the sequelae of chronic liver disease. Here we 
demonstrate that a standardized preparation of silymarin, MK001, as well as two components of 
silymarin, silybin A and silybin B (individually and combined as silibinin), have the ability to 
dose-dependently inhibit T cell proliferation and pro-inflammatory cytokine secretion in vitro. 
Furthermore, MK001 was able to inhibit NF-κB-dependent transcription in Jurkat T cells 
stimulated through T cell receptor engagement, a property that is likely associated with its ability 
to inhibit T cell proliferation and cytokine secretion. These effects suggest that silymarin, at 
sufficiently high oral doses in humans, could potentially result in control of hepatic inflammation 
in chronic liver disease. 
 
The data described herein are in agreement with the limited number of earlier reports regarding 
the effect of silymarin on lymphocyte function and support the notion that silymarin and its 
components can have immunosuppressive/anti-inflammatory effects. Expansion of T cells is 
important step in the amplification of an immune response. Our finding that silymarin inhibited 
antigen-specific and non-specific T cell proliferation extends our knowledge of the inhibitory 
effect of silymarin on cellular proliferation beyond that shown with tumor cell lines7 to freshly 
isolated T cells from HCV-infected and uninfected individuals. With regard to effects on 
cytokine secretion, Schumann et al. described immunosuppressive/anti-inflammatory effects 
upon silibinin pre-treatment in a murine ConA-induced T cell dependent hepatitis 
model.16 Consistent with our in vitro data, elevated intrahepatic mRNA levels of IL-2, IL-4, IFN-
γ and TNF-α and splenocyte secretion of the same cytokines were significantly inhibited by 
silibinin. Other effects included increases in intrahepatic and splenocyte IL-10 levels (which 
differed from our in vitro results), but reinforced the overall immunosuppressive profile of 
silibinin’s effects in their model, as well as reduction in ALT and AST levels and inhibition of 
hepatocyte apoptosis. In a separate report, Lee et al. described silibinin’s ability to inhibit human 
dendritic cell maturation in vitro, which also impacts immune responsiveness.17 
 
Silymarin has a short half-life, with rapid conjugation in the liver and primary excretion in 
bile.18, 19 However, achieving control of hepatic inflammation in vivo will likely require high 
and/or frequent oral dosing of silymarin in its currently available forms. Recently published 
pharmacokinetic analyses of oral Legalon® silymarin in HCV-infected patients described 
steady-state maximum plasma concentrations for free and total (free and conjugated) 
flavonolignans at the 700 mg dose between 0.4-2.7 μg/mL, and 4.1-18.9 μg/mL, respectively,20 
where higher levels of silymarin were found with higher degrees of liver fibrosis.19 It is unclear 
whether free or total levels are relevant for the described bioactive effects; note that the latter 
concentrations are within the range of the anti-inflammatory effects described here and the anti-
viral activity described previously.8 In addition, these plasma values are likely to underestimate 
silymarin levels in the liver. Results from rat21 and human studies18 indicate that the highest 
concentrations are found in liver, suggesting a localization of silymarin effects to this site. As a 
consequence, the likelihood of adverse effects on immune responses generated in lymph nodes or 
at distant sites of infection appears to be relatively low. Whether such effects occur in vivo will 
need to be evaluated directly through trials of silymarin including both pharmacokinetic and 
immunological analyses. Fortunately, silymarin has been described to be very well tolerated, 
even at high doses, making it possible to test whether the dosages required to induce the desired 
anti-inflammatory effects will be safely tolerated. Ideally, such studies to assess the therapeutic 
window for silymarin administration would identify a silymarin dose that would sufficiently 
dampen injurious hepatic immune responses to reduce liver disease progression without inducing 
generalized immunosuppression. The challenge and key to unlocking the promise of silymarin 
will likely be related to the ability to attain optimal concentrations in vivo. 
 
Specifically in the case of HCV infection, however, it is important to consider the possibility that 
the inflammatory lymphocyte response is also likely to be controlling viral replication to some 
degree, such that inhibition of lymphocyte responses could theoretically unleash HCV replication 
and lead to deleterious sequelae. Arguing against this possibility, however, our group previously 
demonstrated that the same preparation of silymarin (MK001), used at the same concentration as 
in this report, inhibited HCV replication in vitro.8 Furthermore, Ferenci et al. have since 
demonstrated that intravenous silibinin decreased circulating HCV RNA levels in humans.22 On 
the basis of these findings taken in toto, we propose a model for potential silymarin efficacy in 
HCV infection which includes both anti-viral and anti-inflammatory effects. We hypothesize that 
decreased hepatic inflammation--due to direct inhibition by silymarin, or due indirectly to 
decreased viral replication, or both--has the potential to induce long-term benefit to the infected 
liver. Future studies will be needed to determine if one effect dominates over the other in vivo, 
although this would not be an issue in situations where hepatic inflammation is not due to viral 
infection. In light of the clearly demonstrated anti-viral effect of silymarin and its components, 
we predict that its immunosuppressive/anti-inflammatory effects are unlikely to lead to 
substantial increases in direct liver injury due to uncontrolled viral replication in hepatitis C. 
 
In summary, we have demonstrated that a standardized preparation of silymarin, MK001, and 
two subcomponents, silybin A and silybin B, were able to dose-dependently inhibit proliferation 
and pro-inflammatory cytokine secretion by freshly isolated PBMC from HCV-infected and 
uninfected subjects. These findings are important, because patients and clinicians have taken a 
keen interest in silymarin as a potential alternative therapy for chronic liver disease, and its 
mechanism of action is incompletely understood. Whether inhibition of T cell proliferation and 
cytokine secretion in vitro might translate into clinical benefit will be determined by randomized 
controlled trials evaluating silymarin efficacy. It is important to note that the potential for clinical 
benefit has already been demonstrated by the recent report of intravenous silibinin which led to 
substantial reduction of HCV RNA levels.22 We speculate that effects on immune function would 
most likely have been detected in this setting, had they been tested. Additional studies are needed 
to better understand the mechanism of action and pharmacokinetics of silymarin both in 
vitro and in vivo, as these data may reveal new indications for the use of this promising 
intervention and provide new benchmarks for effective dosing. 
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